Compugen Ltd. Stock TEL AVIV STOCK EXCHANGE

Equities

CGEN

IL0010852080

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE 10:24:35 2024-07-04 am EDT 5-day change 1st Jan Change
636.5 ILa -0.52% Intraday chart for Compugen Ltd. -4.57% -7.49%
Sales 2024 * 37.04M 13.82B Sales 2025 * 41.12M 15.35B Capitalization 150M 55.81B
Net income 2024 * -4M -1.49B Net income 2025 * -1M -373M EV / Sales 2024 * 4.04 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.64 x
P/E ratio 2024 *
-33.4 x
P/E ratio 2025 *
334 x
Employees 68
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.62%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Compugen Ltd.

1 day-0.52%
1 week-4.57%
Current month-0.84%
1 month-21.03%
3 months-27.43%
6 months-12.56%
Current year-7.49%
More quotes
1 week
631.20
Extreme 631.2
670.00
1 month
631.20
Extreme 631.2
793.60
Current year
631.20
Extreme 631.2
1 175.00
1 year
208.10
Extreme 208.1
1 175.00
3 years
208.10
Extreme 208.1
2 654.00
5 years
208.10
Extreme 208.1
6 766.00
10 years
208.10
Extreme 208.1
6 766.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 01-12-31
Director of Finance/CFO 61 22-10-31
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Chairman 66 17-10-01
Director/Board Member 68 18-06-10
Director/Board Member 57 18-06-10
More insiders
Date Price Change Volume
24-07-04 636.5 -0.52% 31 397
24-07-03 639.8 -3.03% 107,333
24-07-02 659.8 +0.98% 19,591
24-07-01 653.4 +1.79% 14,819
24-06-30 641.9 -0.33% 13,599

Delayed Quote TEL AVIV STOCK EXCHANGE, July 04, 2024 at 10:24 am EDT

More quotes
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.67 USD
Average target price
5 USD
Spread / Average Target
+199.40%
Consensus